Switch to
View more

Bafna Pharmaceuticals Ltd

BAFNAPH
Health CarePharmaceuticals
SmallcapWith a market cap of ₹275 cr, stock is ranked 1,504
Moderate RiskStock is 2.81x as volatile as Nifty
116.550.10 (-0.09%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹275 cr, stock is ranked 1,504
Moderate RiskStock is 2.81x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
53.48
PB RatioPB Ratio
4.86
Dividend YieldDiv. Yield
Sector PESector PE
32.89
Sector PBSector PB
4.57
Sector Div YldSctr Div Yld
0.97%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201920202021202244.0242.7371.9787.24-19.73-25.205.835.16
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Closure of trading window 
Announced OnJun 28, 2022

Bafna Pharmaceuticals Limited has informed the Exchange about Closure of trading window from 1st day of July 2022 till the end of Forty-Eight (48) hours after the declaration of unaudited Financial Results of the Company for the quarter ending 30th June 2022 | Download

Bafna Pharmaceuticals Limited has informed the Exchange about Closure of trading window from 1st day of July 2022 till the end of Forty-Eight (48) hours after the declaration of unaudited Financial Results of the Company for the quarter ending 30th June 2022 | Download

Related Party Transaction 
Announced OnJun 1, 2022

Bafna Pharmaceuticals Limited has informed the Exchange about related party transaction for the period ended March 2022 | Download

Bafna Pharmaceuticals Limited has informed the Exchange about related party transaction for the period ended March 2022 | Download

Cash Dividend 
Ex. DateSep 19, 2013

Final • Div/Share: ₹ 0.6

See all events